Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Efficacy of cancer vaccines in selected gynaecological breast and ovarian cancers: A 20-year systematic review and meta-analysis
Authors
Keywords
Breast cancer, Ovarian cancer, Vaccine, Meta-analysis, Systematic review
Journal
EUROPEAN JOURNAL OF CANCER
Volume 142, Issue -, Pages 63-82
Publisher
Elsevier BV
Online
2020-11-20
DOI
10.1016/j.ejca.2020.10.014
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Strong vaccine responses during chemotherapy are associated with prolonged cancer survival
- (2020) Cornelis J. M. Melief et al. Science Translational Medicine
- Antitumour dendritic cell vaccination in a priming and boosting approach
- (2020) Alexandre Harari et al. NATURE REVIEWS DRUG DISCOVERY
- Are dendritic cells the most appropriate therapeutic vaccine for patients with ovarian cancer?
- (2020) Silvia Martin-Lluesma et al. CURRENT OPINION IN BIOTECHNOLOGY
- Regulatory T cells in cancer immunosuppression — implications for anticancer therapy
- (2019) Yosuke Togashi et al. Nature Reviews Clinical Oncology
- Immunotherapy in Ovarian Cancer: Are We There Yet?
- (2019) Lana E. Kandalaft et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy of adoptive therapy with tumor-infiltrating lymphocytes and recombinant interleukin-2 in advanced cutaneous melanoma: a systematic review and meta-analysis
- (2019) U Dafni et al. ANNALS OF ONCOLOGY
- A phase II randomized, double-blind trial of a polyvalent Vaccine-KLH conjugate (NSC 748933 IND# 14384) + OPT-821 versus OPT-821 in patients with epithelial ovarian, fallopian tube, or peritoneal cancer who are in second or third complete remission: An NRG Oncology/GOG study
- (2019) Roisin E. O’Cearbhaill et al. GYNECOLOGIC ONCOLOGY
- p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy
- (2018) Nicola R. Hardwick et al. CLINICAL CANCER RESEARCH
- Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer Patients
- (2018) Kimberly R. Kalli et al. CLINICAL CANCER RESEARCH
- Update on Tumor Neoantigens and Their Utility: Why It Is Good to Be Different
- (2018) Chung-Han Lee et al. TRENDS IN IMMUNOLOGY
- Evaluation of safety and efficacy of p53MVA vaccine combined with pembrolizumab in patients with advanced solid cancers
- (2018) V. Chung et al. Clinical & Translational Oncology
- Combining Immune Checkpoint Blockade and Tumor-Specific Vaccine for Patients With Incurable Human Papillomavirus 16–Related Cancer
- (2018) Erminia Massarelli et al. JAMA Oncology
- Phase I/II clinical trial of a Wilms’ tumor 1-targeted dendritic cell vaccination-based immunotherapy in patients with advanced cancer
- (2018) Wen Zhang et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- PARP inhibitors in ovarian cancer
- (2018) Elisena Franzese et al. CANCER TREATMENT REVIEWS
- Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a double-blind, randomised, placebo-controlled, phase 3 trial
- (2017) Eric Pujade-Lauraine et al. LANCET ONCOLOGY
- An immunogenic personal neoantigen vaccine for patients with melanoma
- (2017) Patrick A. Ott et al. NATURE
- Vaccine delivery systems
- (2017) Ryan F. Donnelly Human Vaccines & Immunotherapeutics
- A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer
- (2016) Giuseppe Curigliano et al. BREAST CANCER RESEARCH AND TREATMENT
- Triple peptide vaccination as consolidation treatment in women affected by ovarian and breast cancer: Clinical and immunological data of a phase I/II clinical trial
- (2016) MORENA ANTONILLI et al. INTERNATIONAL JOURNAL OF ONCOLOGY
- Update on Poly-ADP-ribose polymerase inhibition for ovarian cancer treatment
- (2016) Anselmo Papa et al. Journal of Translational Medicine
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions
- (2016) Jonathan AC Sterne et al. BMJ-British Medical Journal
- Immunological evaluation of peptide vaccination for cancer patients with the HLA-A26 allele
- (2015) Shinjiro Sakamoto et al. CANCER SCIENCE
- Meta-analysis in clinical trials revisited
- (2015) Rebecca DerSimonian et al. Contemporary Clinical Trials
- Immune Checkpoint Inhibitors for Cancer Therapy: Clinical Efficacy and Safety
- (2015) Saїd Azoury et al. CURRENT CANCER DRUG TARGETS
- A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells
- (2015) B. M. Carreno et al. SCIENCE
- A phase 1/2 study combining gemcitabine, Pegintron and p53 SLP vaccine in patients with platinum-resistant ovarian cancer
- (2015) Eveline M. Dijkgraaf et al. Oncotarget
- Docetaxel Alone or in Combination With a Therapeutic Cancer Vaccine (PANVAC) in Patients With Metastatic Breast Cancer
- (2015) Christopher R. Heery et al. JAMA Oncology
- Association between CD8+ T-cell infiltration and breast cancer survival in 12 439 patients
- (2014) H. R. Ali et al. ANNALS OF ONCOLOGY
- The prognostic value of tumor-infiltrating lymphocytes in triple-negative breast cancer: a meta-analysis
- (2014) Ezzeldin M. Ibrahim et al. BREAST CANCER RESEARCH AND TREATMENT
- Therapeutic DC vaccination with IL-2 as a consolidation therapy for ovarian cancer patients: a phase I/II trial
- (2014) Soyoung Baek et al. Cellular & Molecular Immunology
- Safety and Preliminary Evidence of Biologic Efficacy of a Mammaglobin-A DNA Vaccine in Patients with Stable Metastatic Breast Cancer
- (2014) V. Tiriveedhi et al. CLINICAL CANCER RESEARCH
- Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care
- (2014) Poonamalle Parthasarathy Bapsy et al. CYTOTHERAPY
- Vaccines for the 21st century
- (2014) I. Delany et al. EMBO Molecular Medicine
- Feasibility study of personalized peptide vaccination for recurrent ovarian cancer patients
- (2014) Kouichiro Kawano et al. IMMUNOPHARMACOLOGY AND IMMUNOTOXICOLOGY
- The feasibility and clinical effects of dendritic cell-based immunotherapy targeting synthesized peptides for recurrent ovarian cancer
- (2014) Masanori Kobayashi et al. Journal of Ovarian Research
- A Feasibility Study of Cyclophosphamide, Trastuzumab, and an Allogeneic GM-CSF-Secreting Breast Tumor Vaccine for HER2+ Metastatic Breast Cancer
- (2014) G. Chen et al. Cancer Immunology Research
- Epigenetic Potentiation of NY-ESO-1 Vaccine Therapy in Human Ovarian Cancer
- (2014) K. Odunsi et al. Cancer Immunology Research
- A Dendritic Cell Vaccine Pulsed with Autologous Hypochlorous Acid-Oxidized Ovarian Cancer Lysate Primes Effective Broad Antitumor Immunity: From Bench to Bedside
- (2013) C. L.-L. Chiang et al. CLINICAL CANCER RESEARCH
- Up to 15-year clinical follow-up of a pilot Phase III immunotherapy study in stage II breast cancer patients using oxidized mannan–MUC1
- (2013) Stamatis Vassilaros et al. Immunotherapy
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- Autologous lysate-pulsed dendritic cell vaccination followed by adoptive transfer of vaccine-primed ex vivo co-stimulated T cells in recurrent ovarian cancer
- (2013) Lana E. Kandalaft et al. OncoImmunology
- Autologous dendritic cell vaccine for estrogen receptor (ER)/progestin receptor (PR) double-negative breast cancer
- (2012) Chun-Jian Qi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
- (2012) Erika Hamilton et al. Journal of Translational Medicine
- Efficacy of vaccination with recombinant vaccinia and fowlpox vectors expressing NY-ESO-1 antigen in ovarian cancer and melanoma patients
- (2012) K. Odunsi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CD25 Blockade Depletes and Selectively Reprograms Regulatory T Cells in Concert with Immunotherapy in Cancer Patients
- (2012) A. J. Rech et al. Science Translational Medicine
- A gynecologic oncology group phase II trial of two p53 peptide vaccine approaches: subcutaneous injection and intravenous pulsed dendritic cells in high recurrence risk ovarian cancer patients
- (2011) Osama E. Rahma et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Phase I/II randomized trial of dendritic cell vaccination with or without cyclophosphamide for consolidation therapy of advanced ovarian cancer in first or second remission
- (2011) Christina S. Chu et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Viral Vector-Based Therapeutic Cancer Vaccines
- (2011) Cecilia Larocca et al. CANCER JOURNAL
- MHC Class I-Presented Tumor Antigens Identified in Ovarian Cancer by Immunoproteomic Analysis Are Targets for T-Cell Responses against Breast and Ovarian Cancer
- (2011) M. A. Morse et al. CLINICAL CANCER RESEARCH
- A Live-Attenuated Listeria Vaccine (ANZ-100) and a Live-Attenuated Listeria Vaccine Expressing Mesothelin (CRS-207) for Advanced Cancers: Phase I Studies of Safety and Immune Induction
- (2011) D. T. Le et al. CLINICAL CANCER RESEARCH
- Prognostic significance of tumor-infiltrating T cells in ovarian cancer: A meta-analysis
- (2011) Wei-Ting Hwang et al. GYNECOLOGIC ONCOLOGY
- Long-term clinical and immunological effects of p53-SLP® vaccine in patients with ovarian cancer
- (2011) Ninke Leffers et al. INTERNATIONAL JOURNAL OF CANCER
- Potentiation of a p53-SLP vaccine by cyclophosphamide in ovarian cancer: A single-arm phase II study
- (2011) Renee Vermeij et al. INTERNATIONAL JOURNAL OF CANCER
- Combination therapy of renal cell carcinoma or breast cancer patients with dendritic cell vaccine and IL-2: results from a phase I/II trial
- (2011) Soyoung Baek et al. Journal of Translational Medicine
- Phase I Trial of “bi-shRNAifurin/GMCSF DNA/Autologous Tumor Cell” Vaccine (FANG) in Advanced Cancer
- (2011) Neil Senzer et al. MOLECULAR THERAPY
- Phase III Multicenter Clinical Trial of the Sialyl-TN (STn)-Keyhole Limpet Hemocyanin (KLH) Vaccine for Metastatic Breast Cancer
- (2011) D. Miles et al. ONCOLOGIST
- Phase I Trial of Intraperitoneal Administration of an Oncolytic Measles Virus Strain Engineered to Express Carcinoembryonic Antigen for Recurrent Ovarian Cancer
- (2010) E. Galanis et al. CANCER RESEARCH
- Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial
- (2010) Håkan Norell et al. Journal of Translational Medicine
- Deconstructing the molecular portraits of breast cancer
- (2010) Aleix Prat et al. Molecular Oncology
- A Phase I Trial of Immunotherapy with Lapuleucel-T (APC8024) in Patients with Refractory Metastatic Tumors that Express HER-2/neu
- (2009) P. P. Peethambaram et al. CLINICAL CANCER RESEARCH
- Phase I Active Immunotherapy With Combination of Two Chimeric, Human Epidermal Growth Factor Receptor 2, B-Cell Epitopes Fused to a Promiscuous T-Cell Epitope in Patients With Metastatic and/or Recurrent Solid Tumors
- (2009) Pravin T.P. Kaumaya et al. JOURNAL OF CLINICAL ONCOLOGY
- Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
- (2009) Mary L. Disis et al. JOURNAL OF CLINICAL ONCOLOGY
- Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer
- (2009) Maggie C. U. Cheang et al. JNCI-Journal of the National Cancer Institute
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
- Safety and Immunogenicity Study of NY-ESO-1b Peptide and Montanide ISA-51 Vaccination of Patients with Epithelial Ovarian Cancer in High-Risk First Remission
- (2008) C. S.M. Diefenbach et al. CLINICAL CANCER RESEARCH
- Pilot Study of Vaccination with Recombinant CEA-MUC-1-TRICOM Poxviral-Based Vaccines in Patients with Metastatic Carcinoma
- (2008) J. L. Gulley et al. CLINICAL CANCER RESEARCH
- A Multipeptide Vaccine is Safe and Elicits T-cell Responses in Participants With Advanced Stage Ovarian Cancer
- (2008) Kimberly A. Chianese-Bullock et al. JOURNAL OF IMMUNOTHERAPY
- Clinical and immunological evaluation of anti-apoptosis protein, survivin-derived peptide vaccine in phase I clinical study for patients with advanced or recurrent breast cancer
- (2008) Tetsuhiro Tsuruma et al. Journal of Translational Medicine
- Immunologic and clinical effects of antibody blockade of cytotoxic T lymphocyte-associated antigen 4 in previously vaccinated cancer patients
- (2008) F. S. Hodi et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Phase II Clinical Trial of Bevacizumab and Low-Dose Metronomic Oral Cyclophosphamide in Recurrent Ovarian Cancer: A Trial of the California, Chicago, and Princess Margaret Hospital Phase II Consortia
- (2007) Agustin A. Garcia et al. JOURNAL OF CLINICAL ONCOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now